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Abstract
Aim: To evaluate the outcomes among elderly (≥70 years) and younger patients (<70 years) with
liver-dominant metastatic colorectal cancer (mCRC) who received radioembolization (RE) as salvage
therapy.
Methods: A retrospective review of 107 consecutive patients with unresectable mCRC treated with RE
after failing first- and second-line chemotherapy.
Results: From 2002 to 2012, 44 elderly and 63 younger (<70 years) patients received RE. Patients had
similar previous extensive chemotherapy and liver-directed interventions. Using modified Response
Evaluation Criteria in Solid Tumors (mRECIST) criteria, either a stable or a partial radiographical response
was seen in 65.8% of the younger compared with 76.5% of the elderly patients. RE was equally well
tolerated in both groups and common procedure-related adverse events were predominantly grade 1–2
and of short duration. No significant difference was found with regard to overall median survival between
younger [8.4 months; 95% confidence interval (CI) = 6.2–10.6] or elderly patients (8.2 months; 95% CI =
5.9–10.5, P = 0.667). The presence of extrahepatic disease at the time of RE was associated with a
significantly worse median survival in both groups.
Conclusion: Radioembolization appears to be as well tolerated and effective for the elderly as it is for
younger patients with mCRC. Age alone should not be a discriminating factor for the use of
radioembolization in the management of mCRC patients.
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Introduction
Colorectal cancer (CRC), a leading cause of cancer-related death
worldwide, is predominately a disease of elderly people with
a median age at onset exceeding 70 years.1,2 In 2013, over 142 000
patients were diagnosed with CRC in the United States alone,
and over 50 000 died from this disease.3 The liver is the most
common site of metastases from CRC and 15–25% present with
liver metastases at time of diagnosis.4 In a minority, a liver resection
is feasible and represents the only chance for a cure.4 Even if a
resection is attempted, two-thirds of the patients will develop
recurrence and eventually succumb to their disease.5 Although
patients with unresectable mCRC have a poor outcome, advances
in chemotherapy and availability of biological agents have
improved the median survival in those patients and even rendered
some them resectable.4 Unfortunately, a significant number of
patients have chemorefractory disease and their management
becomes a clinical dilemma.
Radioembolization has emerged as a useful treatment option in
the armamentarium against chemorefractory liver dominant
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metastatic (m)CRC.6–8 In a recent systemic review, Saxena et al.
evaluated 20 studies comprising 979 patients with mCRC who
received radioembolization after failing conventional chemo-
therapy regimens and concluded that radioembolization is both
safe and effective in the salvage setting and should be more widely
utilized. Of interest, this review highlights the preferential treat-
ment of younger patients with radioembolization.9 The median
age of the patients enrolled in the studies was 10 years younger
than the median age at first diagnosis of CRC in the wider patient
population (for instance, 71 years in the United States3). Thus, the
results from the various studies about tolerability and improved
outcomes may not be generalizable to the elderly patients who are
under-represented in the published studies.
As the life expectancy improves with the general population,
discussions on the best ways to manage ageing CRC patients
have become increasingly relevant. Several studies have shown
similar cancer-specific and disease-free survival figures in all
age groups receiving chemotherapy/biological agents or undergo-
ing curative surgery for metastatic colorectal cancer.10–12 The effects
of advancing age on the tolerance and clinical outcomes after
radioembolization in elderly patients are largely unknown. There-
fore, a retrospective analysis was conducted to evaluate the clini-
cal outcomes among elderly compared with younger patients
with liver-dominant mCRC treated in the salvage setting with
radioembolization.
Patients and methods
Patients and radioembolization technique
Patients with chemorefractory liver dominant mCRC who were
treated consecutively with intra-arterial 90Y microspheres between
August 2002 and April 2012 at the University of Pittsburgh Medical
Center were included. Prior to treatments, patients were evaluated
by multidisciplinary teams. Patients eligible to receive RE were
not candidates for a hepatic resection or ablation, had refractory
disease after multiple chemotherapy regimens, an untreated life
expectancy of >12 weeks, Eastern Conference Oncology Group
(ECOG) performance status of 0–2, had adequate hepatic func-
tion (serum total bilirubin <2.0 mg/dl) and had adequate renal
(creatinine <2.0 mg/dl) and haematological function (i.e. granu-
locyte count 1.5 × 109/l, platelets 50 × 109/l). Patients that were
considered for RE had either exhausted or refused standard chemo-
therapy regimens. Patients with extrahepatic metastases were
treated only if the tumour burden outside the liver was <10% of the
total tumour burden, non-progressive extrahepatic disease in the
past 3 months was evidenced by imaging and if chemotherapy
options were not available. Data were recorded via an Institutional
Review Board approved protocol.
The technical details and dosimetry of the process have previ-
ously been described13 but a modified partition model was
employed for the calculation of the 90Y microsphere activity to be
administered to the patient.14 The prescribed activity was calcu-
lated to deliver 50 Gy to the targeted liver tissue. Prior to RE, all
patients underwent selective visceral angiography, a technetium-
99 m-labelled macroaggregated albumin (99mTc-MAA) study
and a baseline computed tomography (CT) or positron emission
tomography (PET)/CT. The selective visceral angiogram allows
for definitive assessment of the arterial anatomy and possible
embolization of vessels that may lead to extrahepatic 90Y exposure.
The 99mTc-MAA study allows pulmonary shunting to be evalu-
ated. The use of RE is avoided if there is any uncorrectable
extrahepatic shunting to the gastrointestinal tract, or >0.6 GBq
(corresponding to a lung dose of 30 Gy) is shunted to the lungs.
RE was administered via unilobar treatments. When bilobar
disease was present, the lobes were treated sequentially with
approximately a 4-week interval. Some patients had multiple
treatments to the same lobe. The determination to treat the same
lobe repetitively was made by evaluating the performance status,
liver function and the extent of extrahepatic disease. However, the
determination to retreat patients was based solely on progression of
disease as assessed via CT. Patients are observed in the hospital
overnight and then discharged the next day with oral narcotics,
proton pump inhibitors and antiemetics.
Follow-up and evaluation
Survival data were acquired from the electronic medical record
and a search of the Social Security Index. All adverse events were
graded using the National Cancer Institute Common Toxicity Cri-
teria Adverse Events Version (CTCAE) 3.0. The nature and sever-
ity of all procedure-related adverse events and laboratory changes
were evaluated from day 1 to month 3 after RE. Patients were
followed with weekly laboratory data and routine office follow-up.
A carcinoembryonic antigen (CEA) response was defined as a
≥50% decrease in post-treatment value from baseline values
obtained at time of RE. Imaging was evaluated for a response to
radioembolization using the modified Response Evaluation Cri-
teria in Solid Tumors (mRECIST) criteria reviewing CT scans
from 1–6 months after treatment. A radiographical response was
graded according to mRECIST. A complete response was defined
as disappearance of any intra-tumoural arterial enhancement in
all target lesions. A partial response was defined as at least a 30%
decrease in the sum of diameters of viable (enhancement in the
arterial phase) target lesions, taking as reference the baseline sum
of the diameters of target lesions. Progressive disease is an increase
of at least 20% in the sum of the diameters of viable (enhancing)
target lesions, taking as reference the smallest sum of the diam-
eters of viable (enhancing) target lesions recorded since treatment
started. Stable disease is any case that does not qualify for either
partial response or progressive disease.15
Statistical analysis
All patients were followed up until death or September 2013.
Statistical analysis was performed using SPSS 17.0 for Windows
(SPSS Inc., Chicago, IL, USA). Descriptive statistics were per-
formed on socio-demographic and disease-specific variables.
Group comparisons on disease-specific variables were performed
using chi-square analyses for categorical variables and Student’s
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t-test for continuous variables. Overall survival (OS) was obtained
by Kaplan–Meier survival analyses (log-rank). Survival was calcu-
lated from the time of first RE to the time of death. The associa-
tion of multiple variables was examined with overall survival
using Cox’s proportional hazard regression analysis. Co-variables
found on univariate analyses to have an association with survival
were included in the model. The Cochran–Mantel–Haenszel was
used to compare the CTCAE distribution between groups. For all
comparisons, significance was at the 0.05 level.
Results
Patient and treatment characteristics
A total of 191 REs were performed in 107 patients during this time
period and data are presented in Table 1. Both groups had similar
baseline liver function tests performance status. Three patients
beyond the inclusion criteria for radioembolization (bilirubin of
2–3 mg/dl) were treated at the discretion of the physician. Both
groups (elderly vs. younger patients) had undergone extensive
chemotherapy prior to radioembolization; 62.8% vs. 68% of
patients received either bevacizumab or cetuximab, 17.1% vs.
28% both, and 22.8% vs. 36% had received prior capecitabine,
respectively.
A greater proportion of younger patients had extrahepatic
disease (including portocaval or retroperitoneal lymphadenopa-
thy, anastomotic recurrence or unresected primary colorectal
tumour, peritoneal disease, bone metastases, and adrenal metas-
tases) at the time of radioembolization, and a non-significant
greater proportion of younger patients had pulmonary nodules at
the time of treatment.
No patients were excluded from treatment owing to either an
unacceptable level of pulmonary shunting or uncorrectable
shunting to the extrahepatic gastrointestinal tract. There were no
differences in the dose administered to the target lobe per treat-
ment, the prescribed activity of 90Y administered, and the activity
Table 1 Baseline patient, disease and treatment characteristics and response among elderly (≥70 years) and younger patients (<70 years)
Characteristic Parameter Age ≥ 70 years Age < 70 years P-value
Gender Male 33(75%) 38 (60.3%) 0.143
Age, years Mean ± SD 75.6 ± 5.4 55.7 ± 8.7 <0.001*
Range 70.0–87.1 37.3–69.2
ECOG performance status 0 26/43 (60.5%) 33/60 (55%) 0.489
1 14/43 (32.6%) 22/60 (36.7%)
2 3/43 (6.9%) 5/60 (8.3%)
Prior procedures Surgical 13/41 (31.7%) 19/61 (31.1%) 0.992
RFA 11/41 (26.8%) 11/61 (18%) 0.331
Extra-hepatic disease Yes 12/41 (29.3%) 29/62 (46.8%) 0.012*
Pulmonary nodules at Rx Yes 14/41 (34.1%) 29/62 (46.8%) 0.052
Total bilirubin, mg/dl Mean ± SD 0.75 ± 0.31 0.74 ± 0.46 0.419
Months from Dx of mCRC to 1st Rx Median (Range) 20.11–175 24.52–92 0.205
Number of treatments Total Number 79 112
1 treatment, n (%) 16 (36.4%) 22 (34.9%)
2 or more treatments, n (%) 28 (63.6%) 41 (65.1%)
Bilobar treatment, n (%) Yes 23 (52.3%) 34 (53.9%) 1.000
Lung shunt (%) Mean ± SD 3.1 ± 2.5 2.9 ± 2.0 0.599
Radiation dose to tissue per treatment Mean ± SD (Gy) 43.6 ± 9.9 45.0 ± 7.0 0.429
Radiation activity given per treatment Mean ± SD (mCi) 28.0 ± 13 30.8 ± 14.4 0.318
Treatments completed with ≥80% of
prescribed dose administered, n (%)
≥80% 64 (81.0%) 94 (83.9%) 0.698
<80%
CEA responsea,c, n (%) ≥50% decrease 10/34 (28.6%) 13/48 (27.1%) 0.966
Radiographic Responsec,d, n (%) Total available 34 41
Partial response 4 (11.8%) 5 (12.2%) 0.998
Stable disease 22 (64.7%) 22 (53.6%) 0.357
Progressive disease 8 (23.5%) 14 (34.2%) 0.445
*Statistically significant.
aCEA response defined as a reduction in CEA ≥50% of the pretreatment level.
bmRECIST criteria used to compare baseline measurement prior to 1st treatment with radiological response during 1–6 months follow-up imaging.
cPercentages calculated based on available data.
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that was actually delivered between the elderly and the younger
patients. All those patients who received <80% of the prescribed
dose had the treatment terminated owing to stagnation of flow
secondary to the embolic process.
Treatment response
There was no significant difference in serial CEA levels available
for review, and in CEA response. Although all patients had base-
line and follow-up imaging obtained, only 34 (77%) elderly
patients and 41 (65%) younger patients had imaging available for
review. No patients had a complete radiological response. There
was no significant difference in radiographical response in the
elderly when compared with the younger patients (Table 1).
Safety and tolerability
Radioembolization was equally well tolerated in both the elderly
and younger patients. Common procedure-related adverse events
(fatigue, nausea and/or vomiting, abdominal pain, fever, and
increased bilirubin) were predominately of mild-to-moderate
intensity and of short duration (Table 2). Two patients in the
elderly group and one patient in the younger group required
readmission within 30 days. Reasons for readmission included an
upper gastrointestinal tract bleed related to oesophageal varices
4 days after treatment in the younger patient, and unresolved
abdominal pain and development of symptomatic brain metasta-
ses in two elderly patients. The post-treatment hepatic toxicity
was assessed between the elderly and younger patients and found
to be relatively mild in both groups. No patient had fulmi-
nant hepatic failure after treatment. One patient in each group
developed a late (after 30 days) grade 4 toxicity that was related to
a biliary stricture and resolved with endoscopic retrograde
cholangiopancreatography and stenting. No patients developed
post-treatment gastric or duodenal ulceration.
Overall survival
Forty-three (97.7%) and 60 (95.2%) patients died during the
follow-up period in the elderly and younger group, respectively.
Six elderly patients and eight younger patients died within 12
weeks of receiving their RE. Kaplan–Meier analysis revealed no
significant difference in survival after radioembolization between
elderly and younger patients [median 8.2 (95% confidence inter-
val (CI) 5.9–10.5) months vs. 8.4 (95% CI 6.2–10.6) months,
respectively; P = 0.351] (Fig. 1).
Univariate and multivariate analyses for the entire cohort and
the different groups are presented in Table 3 and Table 4. For the
entire cohort, extrahepatic disease at the time of treatment was the
only independent predictor of worse overall survival among
the variables examined (Table 3). However, none of the variables
were independent predictors of worse overall survival on multi-
variate analysis in each subgroup when analysed separately
(data not shown).
Further analysis by patient age revealed that the median sur-
vival in the very old (≥75 years, n = 19) and in patients <75 years
(n = 88) was 10.7 (95% CI 2–19.6) and 8.0 (95% CI 6.7–9.2)
months, respectively; P = 0.740. In patients ≥65 years (n = 55) and
<65 years (n = 52), the median survival was 8.0 (95% CI 6.0–9.9)
and 8.4 (95% CI 6.0–10.8) months, respectively; P = 0.452
(Supporting information Figs S1 and S2).
Table 2 Main procedure-related adverse events in the elderly (≥70 years) and younger patients (<70 years) in the first 3 months
post-treatment by severity (CTCAE v3)
CTCAE CTCAE v3: number (%) of patients P-value between
sub-groups
Study sub-group All Grades Grade 1 Grade 2 Grade 3 Grade 4
Fatigue
Age ≥ 70 years 10 (22.7%) 8 (18.1%) 1 (2.3%) 1 (2.3%) –
Age <70 years 15 (23.8%) 12 (19.0%) 2 (3.2%) 1 (1.6%) –
Abdominal pain
Age ≥ 70 yearsr 7 (15.9%) 6 (13.6%) 1 (2.3%) – –
Age < 70 yearsr 12 (19.0%) 9 (14.3%) 2 (3.2%) 1 (1.5%) –
Nausea and/or vomiting
Age ≥ 70 years 12 (27.3%) 9 (20.5%) 2 (4.5%) 1 (2.3%) –
Age < 70 years 20 (31.7%) 16 (25.4%) 4 (6.3%) – –
Fever
Age ≥ 70 years 5 (11.4%) 4 (9.0%) 1 (2.4%) – –
Age <70 years 6 (9.5%) 5 (7.9%) 1 (1.6%) – –
Peak total bilirubina
Age ≥ 70 years 11 (29.7%) 7 (18.9%) – 3 (8.1%) 1 (2.7%)
Age < 70 years 15 (26.8%) 9 (16.0%) 3 (5.4%) 2 (3.6%) 1 (1.8%)
CTCAE v3: Common Terminology Criteria for Adverse Events version 3.0.
aPercentages calculated based on available data.
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Discussion
In this study we attempted to evaluate whether elderly and
younger patients with advanced chemorefractory mCRC under-
going radioembolization have similar outcomes. Golfieri et al.
performed a similar comparison of the survival and tolerability of
radioembolization in patients with unresectable hepatocellular
carcinoma.16 They showed radioembolization to be equally well
tolerated in both elderly and younger patients with no difference
in overall survival. We similarly show that outcomes after
radioembolization in terms of tolerability and efficacy are equiva-
lent between the elderly and younger patients with mCRC. Our
results suggest that elderly patients should be treated with the
same strategy for chemorefractory mCRC as their younger
counterparts, at least as long as there is no severe co-morbidity or
contraindication to radioembolization.
Our study confirmed that the majority of patients were heavily
pretreated irrespective of age. In studying some 15 000 patients,
Egenvall et al. detected a trend towards a less frequent use of
aggressive therapies in elderly patients, but other studies have
shown that for patients who receive aggressive therapy, the treat-
ments are equally tolerated and effective.10,11,17–20 Although the
elderly group is presumed to poorly tolerate more intensive and
invasive treatments, in reality, other factors such as functional
performance rather than pure chronological age may come into
play in the decision making.
The safety analysis addressed the question of whether elderly
patients experienced greater levels of toxicity than younger
patients. Common procedure-related adverse events were pre-
dominately low grade and of short duration but observed
equally in elderly and younger patients. Safety and tolerability
in our study population were similar to previous experiences
with radioembolization for primary and metastatic malignan-
cies.9 An increase in bilirubin to a grade ≥3 in the first 3 months
after radioembolization was observed in a similar proportion
between the elderly and younger patients. In our study, the
observed grade ≥3 CTCAE bilirubin toxicity was similar to
the rate reported (6–14%) in other large studies.16,21 This early
rise in bilirubin reflects some degree of radioembolization-
induced liver disease (REILD) that has been described by
Sangro et al. as a form of sinusoidal obstruction syndrome
appearing 4–8 weeks after radioembolization that is not true
liver decompensation.22,23
Regarding efficacy, our study demonstrated a similar median
survival, regardless of age after radioembolization in both groups.
The median survival in our population was similar to other pub-
lished reports comparing radioembolization to best supportive
care.6,24 Identifying prognostic factors is imperative to optimize
patient selection and improve outcomes. In our study, we identi-
fied the presence of extrahepatic disease to be an independent
predictor of worse overall survival in the entire cohort and asso-
ciated with increased mortality in both the elderly and younger
patients. To date, there is no generalized consensus on recom-
mending radioembolization for patients with extrahepatic
disease. Some centres do not accept any extrahepatic disease,
whereas others accept patients with non-progressive extrahepatic
deposits for treatment.6,7 Limited extra-hepatic disease is currently
not deemed a contraindication to radioembolization at our insti-
tution if this abides by the criteria listed above. In spite of this,
further research is required to establish what burden of disease
and which sites of extra-hepatic disease are most likely associated
with a poor outcome. Of interest, we found that elderly patients
had significantly less extra-hepatic disease at the time of
radioembolization. This difference could be related to delayed
tumour growth (less aggressive tumours) in elderly patients as we
found that younger patients tended to have more advanced
disease and a higher likelihood of presenting with synchronous
disease at the time the cancer was diagnosed. However, this could
also be explained by the fact that a more aggressive approach and
more frequent utilization of radioembolization are adopted when
treating younger patients with extrahepatic disease as compared
with older patients.
Besides radioembolization, other liver-directed intra-arterial
interventions have been evaluated as potential treatment options
for unresectable, chemorefractory mCRC. Unlike radioembo-
lization, bland transarterial embolization has shown no improve-
ment in survival compared with best supportive care. Also, a
Cochrane review concluded that there is minimal if any evidence to
support TAE/TACE in treatment mCRC to the liver.25
Figure 1 Kaplan–Meier analysis of overall survival by age: No sig-
nificant difference was found with regard to overall median survival
between younger or elderly patients (8.4 vs. 8.2 months, P = 0.667)
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The main limitation of the present study is its retrospective
single-centre design although many patients were followed pro-
spectively. This study therefore gives information only about
the patients who were treated. The results must be viewed in light
of the fact that radioembolization was performed in elderly
patients with good performance status and may not be extrapo-
lated to a more frail elderly population with a poor performance
status. Larger and prospective studies are needed to validate these
findings.
In spite of these limitations, our data show that fit elderly
patients should not be excluded from receiving radioembolization
simply on the grounds of advanced age, as it is well tolerated and
effective in this group. Age alone should not be a discriminating
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